EWHealthcare · Medical DevicesThe 29 Wall Street analysts covering Edwards Lifesciences Corp. hold a median 12-month price target of $103 — +18.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Edwards Lifesciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (88): The share price has been relatively steady.
Accruals (69): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EW, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.6% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $110 |
| 11 Sept 2026 | BTIG | Reiterates | Buy | — |
| 11 Sept 2026 | BTIG | Reiterates | Buy | $110 |
| 28 July 2026 | UBS | Assumes | Buy | $110 |
| 25 July 2026 | Leerink Partners | Upgrade | Outperform | — |
| 24 July 2026 | JP Morgan | Maintains | Overweight | — |
| 24 July 2026 | JP Morgan | Maintains | Overweight | $100 → $105 |
| 24 July 2026 | Leerink Partners | Upgrade | Outperform | $87 → $101 |
| 24 July 2026 | Piper Sandler | Reiterates | Overweight | $100 → $101 |
| 24 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | $90 → $95 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $100 → $105 |
| 13 July 2026 | RBC Capital | Maintains | Outperform | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | $100 → $110 |
| 8 July 2026 | Citigroup | Maintains | Buy | $101 → $110 |
| 8 July 2026 | Citigroup | Maintains | Buy | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $93 → $100 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EW appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Edwards Lifesciences Corp. returned +17.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 14% of US stocks
Cheaper than 17% of US stocks
Cheaper than 21% of US stocks
Cheaper than 12% of US stocks
Higher than 60% of US stocks
Higher than 17% of US stocks
Higher than 89% of US stocks
Higher than 87% of US stocks
Higher than 78% of US stocks
Higher than 61% of US stocks
Higher than 89% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Edwards Lifesciences Corp. has a market value of $49.8B and an enterprise value of $46.4B.
Revenue in the twelve months to 30 June 2026: $6.5B. The latest quarter grew 13.6% year on year.
Net income over the same four quarters: $1.0B, a 15.4% net margin.
Diluted earnings per share, trailing twelve months: $1.74.
Free cash flow in the twelve months to 30 June 2026: $1.4B, after $286.7M of capital spending.
Edwards Lifesciences Corp. spent $1.2B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 52.0×; forward P/E: 25.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Edwards Lifesciences Corp. employs 16,000 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Edwards Lifesciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Edwards Lifesciences plans to report operating results for the quarter ended Sept. 30, 2026, after market close on Nov. 4, 2026. The company will host a conference call that day at 5:00 p.m. ET, available by phone and through its Investor Relations website.
Why it matters — EW watchers can use the scheduled announcement and call to hear the company discuss its quarterly results.
Edwards Lifesciences announced it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The event will feature a live Q&A session with physicians and members of the Edwards management team, with a webcast available on the investor relations website.
Why it matters — An EW watcher would care because the investor event offers a scheduled opportunity to hear directly from physicians and Edwards management, which could provide insight into the company's perspectives around the TCT symposium.
Edwards Lifesciences announced that the U.S. Food and Drug Administration has approved the AUTUS Size-Adjustable Valve, the first FDA-approved surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.
Why it matters — The FDA approval expands Edwards Lifesciences' product portfolio into a previously unserved pediatric pulmonary valve market.
Edwards Lifesciences outlined a strategy focused on structural heart disease, with CEO Bernard Zovighian identifying five principal growth platforms: transcatheter aortic valve replacement, PASCAL, EVOQUE, SAPIEN M3, and surgical therapies.
Why it matters — A EW watcher would care because the company is framing its TAVR expansion and broader structural-heart pipeline as its central growth strategy.
Edwards Lifesciences Corporation presented at the Deutsche Bank 2026 Healthcare Summit, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation in the investor conference.
Why it matters — A transcript of Edwards Lifesciences' presentation at a major investor summit offers EW watchers insight into what the company communicated directly to the financial community.
The 29 Wall Street analysts covering Edwards Lifesciences Corp. have a median 12-month price target of $103, with estimates ranging from $84 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Edwards Lifesciences Corp., 23 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edwards Lifesciences Corp. 93 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Edwards Lifesciences Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (88 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +18.6% from the last close, and Ticker Nerd's factor model ranks Edwards Lifesciences Corp. 93 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Edwards Lifesciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $110 over the next 12 months.
Edwards Lifesciences Corp. returned +17.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves.
The most recent item we track (Business Wire, 7 Oct 2026): "Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026". Edwards Lifesciences plans to report operating results for the quarter ended Sept. 30, 2026, after market close on Nov. 4, 2026. The company will host a conference call that day at 5:00 p.m. ET, available by phone and through its Investor Relations website.
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
CEO Mr. Bernard J. Zovighian · 16,000 employees · United States · https://www.edwards.com
